Pharm Exec 50: Growth from the Bottom Up - Pharmaceutical Executive

ADVERTISEMENT

Pharm Exec 50: Growth from the Bottom Up


Pharmaceutical Executive


The Top 10 Year In Review

1. Pfizer faced a brutal year of patent expirations in 2011, including not just US exclusivity loss for its leading product, Lipitor, but Aromasin, Xalatan, Vfend, and Protonix as well. Still, the industry giant had five products that sold $2 billion or more, and revenues that topped $500 million in 18 countries outside the US. It also acquired King for $3.6 billion, providing a broader profile in pain, and sold formulation specialist Capsugel. Approvals included Xalkori (crizotinib) for some lung cancers with the ALK gene.

2. Novartis won 15 approvals in the United States, the EU, and Japan. Among them was US approval for Arcapta Inhalr for COPD. It also launched the oral MS drug Gilenya. While still integrating Alcon, the world's largest eyecare company, acquired last year, Novartis bought Genoptix, a diagnostics company, for $458 million, and hit a key landmark as Sandoz's generic version of the anticoagulant enoxaparin became the company's first "generic blockbuster," with sales of more than $1 billion.

3. Merck gained FDA and EU approval for Victrelis, the first new medicine for chronic hepatitis C in almost a decade. Other approvals included Juvisync, a combination of the diabetes drug Januvia with the statin Zocor. Merck also bought Inspire, an ophthalmic specialty firm, for $430 million and formed alliances with India's Sun Pharma (to promote branded generics in emerging markets) and Parexel (to pursue biosimilars). As the year ended, CEO Kenneth Frazier was appointed chairman, replacing Richard Clark.

4. Sanofi acquired Genzyme for $20 billion in April, the largest of 30 new transactions in 2011. Others included the acquisition of pediatric specialist Topaz Pharmaceuticals and Universal Medicare, a consumer health company in India. Jevtana, for advanced prostate cancer, launched in Europe, and the Allegra family of allergy products launched in the US on an over-the-counter basis. Lost market exclusivity included Taxotere, Xatral, and Nasacort in the US and Aprovel in Western Europe.

5. Roche gained simultaneous FDA approval for Zelboraf, a targeted therapy for metastatic melanoma, and its companion diagnostic test—a first. It also acquired Anadys, a hepatitis C specialist, for $230 million, and announced a partnership with Evotec to develop oncology biomarkers. In a controversial decision, FDA withdrew approval of Roche's Avastin for breast cancer—though CMS announced it would continue to reimburse for it. For the first time, the family-owned bloc of Roche shares dipped below 50 percent when Maia Oeri dropped out of the group.

6. GlaxoSmithKline announced the $660 million sale of 17 noncore OTC brands, including Beano, Goody's, Ecotrin, Fiber Choice, Sominex, and Tagamet, to Prestige Brands. US approvals included Benlysta, the first new lupus treatment in more than 50 years (developed with Human Genome Sciences); the anticonvulsant Potigal (developed with Valeant); and Horizant for restless leg syndrome (developed with XenoPort).

7. AstraZeneca sold its Astra Tech subsidiary, which makes dental implants and medical devices for surgery and urology, to Dentsply for $1.8 billion. FDA approved Brilinta, AZ's new anticoagulant, reversing its 2010 rejection of the drug, as well as giving the nod to Caprelsa, the first approved therapy for nonoperable advanced medullary thyroid cancer, an orphan condition. Meanwhile, Japanese regulators approved Nexium—a decade after the drug's US launch.

8. Johnson & Johnson, while struggling to put manufacturing problems behind it, took a commanding position in the orthopedic market with its $21.3 billion acquisition of medical-equipment maker Synthes. It won approval for Zytiga (for late-stage prostate cancer) and the anticoagulant Xarelto. J&J exited the drug-eluting stent market it helped create. It sold off its Jannsen dermatology business and the US rights to St. Joseph's aspirin, and bought the over-the-counter brands of India's J.B. Chemicals & Pharmaceuticals.

9. Abbott announced plans to split itself into two companies: a medical products company focused on medical devices, branded generics, and nutritionals; and a research-based pharmaceutical company. The spinoff is slated to take place late this year. Abbott also received European approval for a new absorbable heart stent, and filed for multiple new indications for Humira.

10. Eli Lilly successfully fended off a challenge to its Cymbalta patent in federal court, preserving its market exclusivity until at least June 2013. It won US and EU market approval for Bydureon, the diabetes drug it developed with Amylin, only to have the nine-year-old partnership break up in November. It announced a strategic alliance with Boehringer Ingelheim focused on diabetes. The partnership won US and UK approval for Tradjenta/Trajenta. In July, Lilly acquired the animal health business of Janssen, a Johnson & Johnson company.

About the Authors

Jerry Cacciotti is a Partner in Oliver Wyman's Health and Life Sciences Practice. He can be reached at

Patrick Clinton is Marketing Director in the Health & Life Sciences practice of Oliver Wyman. He can be reached at


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here